Cardiology

Past APAC President Viet Le shares insights from CAPP 2024 on managing high-risk ASCVD, new non-statin therapies, and options for statin-intolerant patients.

Masri discussed the new phase 3 trial of Intellia’s NTLA-2001 or nex-z.

The Pressure Check study at Yale aims to address disparities in blood pressure management.

HCPLive takes a look at one of the newer fields investigating gene therapy, which has been enabled by trials and approvals in hematology, ophthalmology, and other spaces.

The VARIPULSE platform enables AF treatment with a single device combining pulsed field ablation therapy and mapping with the CARTO 3 system.

Work-related stress associated with adverse cardiovascular health in diverse US adult population, indicating potential risk factor for CVD prevention.

In the final part of this 5-part series, Lala-Trindade discusses the findings of the FINEARTS-HF trial and how it might inform use of finerenone.

In part 4 of this 5-part series, discussants explore the influence of recent guidelines on changing standards of CKD care.

In part 3 of this 5-part series, Lerma discusses recent updates in the management of chronic kidney disease in people with type 2 diabetes.

In part 2 of this 5-part series, Lerma and Lala-Trindade discuss the key differences in MoA for nsMRA and MRAs.

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

Katherine Tuttle, MD, joins the podcast for a deep dive into the latest FLOW data from Kidney Week 2024.

Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.

New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.

New FINEARTS-HF data shows that finerenone reduces albuminuria in patients with HFmrEF or HFpEF, but without significant eGFR changes.

Masri previewed data to be presented at the AHA 2024 Scientific Sessions and shared his excitement for the ongoing phase 3 trial of NTLA-2001.

Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.

A study found that adding depression to Life's Essential 8 provides minimal improvements in predicting cardiovascular and all-cause mortality risk.

A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.

In part 3 of our Special Report on lipoprotein apheresis, Sperling and Gianos discuss future considerations for use and the evolving landscape of lipid management.

In part 2 of this 3-part series, Sperling and Gianos highlight the role of lipoprotein apheresis in contemporary settings and the supporting evidence base.

Laurence Sperling, MD, and Eugenia Gianos, MD, discuss the historical context and underutilization of lipoprotein apheresis in part 1 of a 3-part video series.

Linda Gillam, MD, MPH, discusses updates in the management of aortic stenosis, with a focus on use of TAVR.

The sNDA submission to the FDA included a Priority Review Voucher, which commits the regulatory agency to an accelerated review timeline.

Linda Gillam, MD, MPH, discusses the idea that the cardiology community may. be overtreating aortic stenosis.